Jennifer J Gantzer*

Department of Clinical Sciences, National University of Health Sciences, USA

*Corresponding Author: Jennifer J Gantzer, Department of Clinical Sciences, National University of Health Sciences, USA.

Received: March 22, 2022; Published: June 24, 2022

Abstract

IBS is a functional gut disorder with abdominal pain and discomfort, bloating, urgency, irregular bowel habits, and increased sensation to bowel contents, the latter called visceral hypersensitivity. IBS treatments are historically unrewarding and unsuccessful for both the patients and providers. Quantitative research has provided a better understanding of the pathological etiology of visceral hypersensitivity and its role in abdominal pain. Qualitative research highlights the emotional struggles of patients coping with IBS and the impact on their life and daily routines. This article spotlights using a combination of quantitative and qualitative research methods to better understand visceral hypersensitivity and treatments addressing it for improved clinical outcomes.

Keywords: IBS; Visceral Hypersensitivity; NGF; CRF; Stress; Cognitive Therapy

References

1. Rome Foundation. What’s new for Rome IV (2022).
2. , et al. “Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome”. Gastroenterology 148.5 (2015): 1002-1011.e4.
3. Xu XJ., et al. “Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhea-predominant irritable bowel syndrome: a preliminary explorative study”. Alimentary Pharmacology and Therapeutics 45 1 (2017): 100-114.
4. Zhou Q and Verne GN. “New insights into visceral hypersensitivity--clinical implications in IBS”. Nature Reviews Gastroenterology and Hepatology 6 (2011): 349-355.
5. Kinsinger SW. “Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights”. Psychology Research and Behavior Management 10 (2017): 231-237.
6. Jacobs JP., et al. “Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement”. Microbiome 1 (2021): 236.
7. Rome Foundation. (n.d.) Rome IV Criteria. Functional Gastrointestinal Interactions (2022).
8. Business Wire. “Global Irritable Bowel Syndrome (IBS) Market Outlook Report 2022: Opportunity and Demand Analysis and Market Forecasts, 2019-2028 - Research and Markets.com”.
9. International Foundation for Gastrointestinal Disorders (IFFGD). About IBS. Statistics (2022).
10. Harkness EF., et al. “GP perspectives of irritable bowel syndrome an accepted illness, but management deviates from guidelines: a qualitative study”. BMC Family Practice 14 (2013): 92.
11. Bertram S., et al. “The patient's perspective of irritable bowel syndrome”. The Journal of Family Practice6 (2001): 521-525.
12. McGregor S. “Research methodologies. In Understanding and evaluating research”. SAGE Publications, Inc (2018).
13. Botschuijver S., et al. “Intestinal Fungal Dysbiosis Is Associated with Visceral Hypersensitivity in Patients with Irritable Bowel Syndrome and Rats”. Gastroenterology 4 (2017): 1026-1039.
14. Latorre R., et al. “Enteroendocrine cells: a review of their role in brain-gut communication”. Neurogastroenterology and Motility 5 (2016): 620-630.
15. Larauche M., et al. “Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications”. Journal of Physiology and Pharmacology 7 (2009): 33-46.
16. Qin HY., et al. “Impact of psychological stress on irritable bowel syndrome”. World Journal of Gastroenterology 39 (2014): 14126-14131.
17. Kanczkowski W., et al. “Adrenal Gland Microenvironment and Its Involvement in the Regulation of Stress-Induced Hormone Secretion during Sepsis”. Frontiers in Endocrinology (Lausanne) 7 (2016): 156.
18. Konturek PC., et al. “Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options”. Indian Journal of Physiology and Pharmacology 6 (2011): 591-599.
19. Guilliams G. “The Role of Stress and the HPA Axis in Chronic Disease Management”. Point Institute (2018).
20. Hearn M., et al. “Stigma and irritable bowel syndrome: a taboo subject?” The Lancet Gastroenterology and Hepatology 6 (2020): 607-615.
21. Ahmad OF and Akbar A. “Dietary treatment of irritable bowel syndrome”. British Medical Bulletin 1 (2015): 83-90.
22. Frändemark Å., et al. “Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with irritable bowel syndrome”. BMC Gastroenterology1 (2022): 73.
23. Paine P. “Review article: current and future treatment approaches for pain in IBS”. Alimentary Pharmacology and Therapeutics1 (2021): S75-S88.
24. Jagielski CH and Riehl ME. “Behavioral Strategies for Irritable Bowel Syndrome: Brain-Gut or Gut-Brain?” Gastroenterology Clinics of North America 3 (2021): 581-593.
25. Dainty AD., et al. “A mixed methods feasibility study to evaluate the use of a low-intensity, nurse-delivered cognitive behavioural therapy for the treatment of irritable bowel syndrome”. BMJ Open6 (2014): e005262.
26. Maddux MH., et al. “Using a Mixed-method Approach to Develop a Transition Program for Young Adults with Inflammatory Bowel Disease”. Journal of Pediatric Gastroenterology and Nutrition 2 (2020): 195-199.

Citation

Citation: Jennifer J Gantzer. “Insight into Improved IBS Clinical Outcomes Using a Combination of Quantitative and Qualitative Research Methods to Better Understand Visceral Hypersensitivity and Treatments Addressing it". Acta Scientific Neurology 5.7 (2022): 23-29.

Copyright

Copyright: © 2022 Jennifer J Gantzer. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.